Literature DB >> 20131059

Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing.

Jörg Felsberg1, Marietta Wolter, Heike Seul, Britta Friedensdorf, Matthias Göppert, Michael C Sabel, Guido Reifenberger.   

Abstract

Diffusely infiltrating cerebral gliomas frequently carry point mutations in codon 132 of the isocitrate dehydrogenase 1 (IDH1) gene or in codon 172 of the IDH2 gene, which are both clinically important as diagnostic and prognostic markers. Here, we report on a method that allows for the rapid detection of IDH1 and IDH2 mutations based on pyrosequencing. The method is applicable to routinely processed tissue specimens and provides quantitative mutation data within less than one working day. Due to its high sensitivity, the technique may also be used for the diagnostic assessment of IDH1 or IDH2 mutation in tissue samples with low tumor cell content, such as the infiltration zone of diffuse gliomas. Using pyrosequencing and/or conventional cycle sequencing of IDH1 and IDH2 in 262 gliomas, we confirm frequent mutations in diffuse astrocytic and oligodendroglial gliomas, corroborate a prognostic role for IDH1 mutation in primary glioblastomas and show that pleomorphic xanthoastrocytomas generally lack mutations in these genes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20131059     DOI: 10.1007/s00401-010-0647-4

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   15.887


  33 in total

1.  Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.

Authors:  Xianyuan Song; R Andrew Allen; S Terence Dunn; Kar-Ming Fung; Peter Farmer; Shital Gandhi; Tulika Ranjan; Alexis Demopoulos; Marc Symons; Michael Schulder; Jian Yi Li
Journal:  Int J Clin Exp Pathol       Date:  2011-09-17

2.  Molecular profile of oligodendrogliomas in young patients.

Authors:  Vaishali Suri; Prerana Jha; Shipra Agarwal; Pankaj Pathak; Mehar Chand Sharma; Vikas Sharma; Sudhanshu Shukla; Kumaravel Somasundaram; Ashok Kumar Mahapatra; Shashank Sharad Kale; Chitra Sarkar
Journal:  Neuro Oncol       Date:  2011-10       Impact factor: 12.300

Review 3.  Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.

Authors:  Changcun Guo; Christopher J Pirozzi; Giselle Y Lopez; Hai Yan
Journal:  Curr Opin Neurol       Date:  2011-12       Impact factor: 5.710

4.  Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.

Authors:  Elisa De Carlo; Lorenzo Gerratana; Giovanna De Maglio; Vanessa Buoro; Francesco Cortiula; Lorena Gurrieri; Miriam Isola; Gianpiero Fasola; Fabio Puglisi; Stefano Pizzolitto; Simona Rizzato
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

Review 5.  Using the molecular classification of glioblastoma to inform personalized treatment.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  J Pathol       Date:  2014-01       Impact factor: 7.996

6.  Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.

Authors:  Eric Aliotta; Prem P Batchala; David Schiff; Beatriz M Lopes; Jason T Druzgal; Sugoto Mukherjee; Sohil H Patel
Journal:  J Neurooncol       Date:  2019-09-17       Impact factor: 4.130

7.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

8.  How molecular testing can help (and hurt) in the workup of gliomas.

Authors:  Kenneth Clark; Zoya Voronovich; Craig Horbinski
Journal:  Am J Clin Pathol       Date:  2013-03       Impact factor: 2.493

Review 9.  Molecular diagnostics of gliomas: state of the art.

Authors:  Markus J Riemenschneider; Judith W M Jeuken; Pieter Wesseling; Guido Reifenberger
Journal:  Acta Neuropathol       Date:  2010-08-17       Impact factor: 17.088

10.  Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Authors:  Shipra Agarwal; Mehar Chand Sharma; Prerana Jha; Pankaj Pathak; Vaishali Suri; Chitra Sarkar; Kunzang Chosdol; Ashish Suri; Shashank Sharad Kale; Ashok Kumar Mahapatra; Pankaj Jha
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.